{"id":450906,"date":"2021-03-04T09:45:34","date_gmt":"2021-03-04T14:45:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450906"},"modified":"2021-03-04T09:45:34","modified_gmt":"2021-03-04T14:45:34","slug":"aquestive-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-notifies-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-co","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aquestive-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-notifies-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-co\/","title":{"rendered":"AQUESTIVE THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP notifies investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey"},"content":{"rendered":"

\nLEAD PLAINTIFF DEADLINE IS APRIL 30, 2021
\n<\/h2>\n
\n

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP <\/a> announces that a federal securities class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) in\u00a0 United States District Court for the District of New Jersey. The class action is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Aquestive securities between December 2, 2019 and September 25, 2020, both dates inclusive (the “Class Period\u201d).<\/p>\n

\n All investors who purchased shares of Aquestive Therapeutics, Inc.<\/strong>
\n and incurred losses are urged to contact the firm immediately at <\/strong>
\n
\n classmember@whafh.com<\/strong>
\n <\/a>
\n or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or <\/strong>
\n
\n join the case<\/strong>
\n <\/a>
\n on our website, <\/strong>
\n
\n www.whafh.com.<\/strong>
\n <\/a>\n <\/p>\n

If you have incurred losses in the shares of Aquestive Therapeutics, Inc., you may,<\/strong>no later than April 30, 2021, <\/strong>request that the Court appoint you lead plaintiff of the proposed class.\u00a0\u00a0 Please contact Wolf Haldenstein<\/a> to learn more about your rights as an investor in the shares of Aquestive Therapeutics, Inc.<\/p>\n

\n
\n CLICK HERE TO JOIN CASE<\/a>
\n <\/strong>\n <\/p>\n

On December 2, 2019, Aquestive announced the completion of the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for Libervant Buccal Film for the management of seizure clusters (the “Libervant NDA”).<\/p>\n

The filed complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and\/or misleading statements and\/or failed to disclose that:<\/p>\n